Lansbury Louise E, Smith Sherie, Beyer Walter, Karamehic Emina, Pasic-Juhas Eva, Sikira Hana, Mateus Ana, Oshitani Hitoshi, Zhao Hongxin, Beck Charles R, Nguyen-Van-Tam Jonathan S
University of Nottingham, Nottingham, UK.
University of Nottingham, Nottingham, UK.
Vaccine. 2017 Apr 11;35(16):1996-2006. doi: 10.1016/j.vaccine.2017.02.059. Epub 2017 Mar 14.
The clinical effectiveness of monovalent influenza A(H1N1)pdm09 vaccines has not been comprehensively summarised. We undertook a systematic review and meta-analysis to assess vaccine effectiveness (VE) for adjuvanted and unadjuvanted vaccines.
We searched healthcare databases and grey literature from 11 June 2009 to 12 November 2014. Two researchers independently assessed titles and abstracts to identify studies for full review. Random effects meta-analyses estimated the pooled effect size of vaccination compared to placebo or no vaccination for crude and adjusted odds ratios (OR) to prevent laboratory confirmed influenza illness (LCI) and related hospitalization. VE was calculated as (1-pooled OR)∗100. Narrative synthesis was undertaken where meta-analysis was not possible.
We identified 9229 studies of which 38 at moderate risk of bias met protocol eligibility criteria; 23 were suitable for meta-analysis. Pooled adjusted VE against LCI with adjuvanted and unadjuvanted vaccines both reached statistical significance (adjuvanted: VE=80%; 95% confidence interval [CI] 59-90%; unadjuvanted: VE=66%; 95% CI 47-78%); in planned secondary analyses, VE in adults often failed to reach statistical significance and pooled point estimates were lower than observed in children. Overall pooled adjusted VE against hospitalization was 61% (95% CI 14-82%); in planned secondary analyses, adjusted VE attained statistical significance in adults aged 18-64years and children for adjuvanted vaccines. Adjuvanted vaccines were significantly more effective in children compared to adults for both outcomes.
Adjuvanted and unadjuvanted monovalent influenza A(H1N1)pdm09 vaccines were both effective in preventing LCI. Overall, the vaccines were also effective against influenza-related hospitalization. For both outcomes adjuvanted vaccines were more effective in children than in adults.
甲型H1N1流感大流行单价疫苗的临床效果尚未得到全面总结。我们进行了一项系统评价和荟萃分析,以评估佐剂疫苗和非佐剂疫苗的疫苗效力(VE)。
我们检索了2009年6月11日至2014年11月12日期间的医疗保健数据库和灰色文献。两名研究人员独立评估标题和摘要,以确定进行全面审查的研究。随机效应荟萃分析估计了与安慰剂或未接种疫苗相比,接种疫苗预防实验室确诊流感疾病(LCI)及相关住院的合并效应大小,以粗比值比(OR)和调整后的OR计算。VE的计算方法为(1-合并OR)×100。在无法进行荟萃分析的情况下进行叙述性综合分析。
我们识别出9229项研究,其中38项偏倚风险为中度的研究符合方案纳入标准;23项适合进行荟萃分析。佐剂疫苗和非佐剂疫苗预防LCI的合并调整后VE均达到统计学显著性(佐剂疫苗:VE = 80%;95%置信区间[CI] 59 - 90%;非佐剂疫苗:VE = 66%;95% CI 47 - 78%);在计划的二次分析中,成人的VE往往未达到统计学显著性,合并点估计值低于儿童。总体合并调整后预防住院的VE为61%(95% CI 14 - 82%);在计划的二次分析中,佐剂疫苗在18 - 64岁成人和儿童中的调整后VE达到统计学显著性。对于这两个结果,佐剂疫苗在儿童中比在成人中显著更有效。
佐剂和非佐剂甲型H1N1流感大流行单价疫苗在预防LCI方面均有效。总体而言,这些疫苗对流感相关住院也有效。对于这两个结果,佐剂疫苗在儿童中比在成人中更有效。